{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T19:31:56Z","timestamp":1648755116015},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,11,9]],"date-time":"2013-11-09T00:00:00Z","timestamp":1383955200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s00108-013-3323-7","type":"journal-article","created":{"date-parts":[[2013,11,7]],"date-time":"2013-11-07T08:58:40Z","timestamp":1383814720000},"page":"1434-1442","source":"Crossref","is-referenced-by-count":1,"title":["Therapie des multiplen Myeloms"],"prefix":"10.1007","volume":"54","author":[{"given":"D.","family":"Peest","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,9]]},"reference":[{"key":"3323_CR1","unstructured":"o\u00a0A (2009) Sekund\u00e4re Immundefektkrankheiten. In: Bundes\u00e4rztekammer (Hrsg) Querschnitts-Leitlinien (B\u00c4K) zur Therapie mit Blutkomponenten und Plasmaderivaten. Deutscher \u00c4rzte-Verlag, K\u00f6ln"},{"key":"3323_CR2","unstructured":"o\u00a0A (2013) Myeloma. In: Howlader\u00a0N, Noone\u00a0AM, Krapcho\u00a0M et\u00a0al (Hrsg) SEER Cancer Statistics Review, 1975\u20132010, based on November 2012 SEER data submission, National Cancer Institute. Bethesda. http:\/\/seer.cancer.gov\/csr\/1975_2010\/"},{"key":"3323_CR3","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/bmt.2012.173","volume":"48","author":"Armeson","year":"2013","unstructured":"Armeson KE, Hill EG, Costa LJ (2013) Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment. Bone Marrow Transplant 48:562\u2013567","journal-title":"Bone Marrow Transplant"},{"key":"3323_CR4","doi-asserted-by":"crossref","unstructured":"Attal M, Harousseau JL, Stoppa AM et\u00a0al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N\u00a0Engl J Med 335:91\u201397","DOI":"10.1056\/NEJM199607113350204"},{"key":"3323_CR5","doi-asserted-by":"crossref","unstructured":"Barlogie B, Anaissie E, Rhee F van et\u00a0al (2010) Reiterative survival analyses of total therapy\u00a02 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms. J\u00a0Clin Oncol 28:3023\u20133027","DOI":"10.1200\/JCO.2009.26.4465"},{"key":"3323_CR6","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1182\/blood.V88.12.4711.bloodjournal88124711","volume":"88","author":"Bj\u00f6rkstrand","year":"1996","unstructured":"Bj\u00f6rkstrand B, Ljungman P, Svensson H et\u00a0al (1996) Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Bone Marrow Transplantation. Blood 88:4711\u20134718","journal-title":"Blood"},{"key":"3323_CR7","doi-asserted-by":"crossref","unstructured":"Child JA, Morgan GJ, Davies FE et\u00a0al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N\u00a0Engl J Med 348:1875\u20131883","DOI":"10.1056\/NEJMoa022340"},{"key":"3323_CR8","doi-asserted-by":"crossref","unstructured":"Corradini P, Voena C, Tarella C et\u00a0al (1999) Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J\u00a0Clin Oncol 17:208","DOI":"10.1200\/JCO.1999.17.1.208"},{"key":"3323_CR9","doi-asserted-by":"crossref","unstructured":"Dudeney S, Lieberman IH, Reinhardt MK et\u00a0al (2002) Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma. J\u00a0Clin Oncol 20:2382\u20132387","DOI":"10.1200\/JCO.2002.09.097"},{"key":"3323_CR10","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","volume":"370","author":"Facon","year":"2007","unstructured":"Facon T, Mary JY, Hulin C et\u00a0al (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM\u00a099-06): a randomised trial. Lancet 370:1209\u20131218","journal-title":"Lancet"},{"key":"3323_CR11","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1182\/blood-2012-11-469452","volume":"121","author":"Gahrton","year":"2013","unstructured":"Gahrton G, Iacobelli S, Bj\u00f6rkstrand B et\u00a0al (2013) Autologous\/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood 121:5055\u20135063","journal-title":"Blood"},{"key":"3323_CR12","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","volume":"121","author":"International","year":"2003","unstructured":"International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121:749\u2013757","journal-title":"Br J Haematol"},{"key":"3323_CR13","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A et\u00a0al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516\u20132520","journal-title":"Blood"},{"key":"3323_CR14","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","volume":"24","author":"Kyle","year":"2010","unstructured":"Kyle RA, Durie BGM, Rajkumar SV et\u00a0al (2010) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24:1121\u20131127","journal-title":"Leukemia"},{"key":"3323_CR15","doi-asserted-by":"crossref","unstructured":"Kyle RA, Remstein ED, Therneau TM et\u00a0al (2007) Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N\u00a0Engl J Med 356:2582\u20132590","DOI":"10.1056\/NEJMoa070389"},{"key":"3323_CR16","doi-asserted-by":"crossref","unstructured":"Kyle RA, Therneau TM, Rajkumar SV et\u00a0al (2006) Prevalence of monoclonal gammopathy of undetermined significance. N\u00a0Engl J Med 354:1362\u20131369","DOI":"10.1056\/NEJMoa054494"},{"key":"3323_CR17","doi-asserted-by":"crossref","unstructured":"Kyle RA, Therneau TM, Rajkumar SV et\u00a0al (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N\u00a0Engl J Med 346:564\u2013569","DOI":"10.1056\/NEJMoa01133202"},{"key":"3323_CR18","first-page":"295","volume":"2010","author":"Landgren","year":"2010","unstructured":"Landgren O (2010) Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology. ASH Education Program Book 2010:295\u2013302","journal-title":"ASH Education Program Book"},{"key":"3323_CR19","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1182\/blood.V90.10.4206","volume":"90","author":"Lokhorst","year":"1997","unstructured":"Lokhorst HM, Schattenberg A, Cornelissen JJ et\u00a0al (1997) Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 90:4206\u20134211","journal-title":"Blood"},{"key":"3323_CR20","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1182\/blood-2003-11-3862","volume":"103","author":"Lokhorst","year":"2004","unstructured":"Lokhorst HM, Wu K, Verdonck LF et\u00a0al (2004) The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 103:4362\u20134364","journal-title":"Blood"},{"key":"3323_CR21","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1182\/blood-2011-11-374249","volume":"119","author":"Ludwig","year":"2012","unstructured":"Ludwig H, Durie BGM, McCarthy P et\u00a0al (2012) IMWG consensus on maintenance therapy in multiple myeloma. Blood 119:3003\u20133015","journal-title":"Blood"},{"key":"3323_CR22","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood-2011-01-332320","volume":"118","author":"Martinez-Lopez","year":"2011","unstructured":"Martinez-Lopez J, Blade J, Mateos MV et\u00a0al (2011) Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 118:529\u2013534","journal-title":"Blood"},{"key":"3323_CR23","doi-asserted-by":"crossref","unstructured":"Mateos M-V, Hern\u00e1dez M-T, Giraldo P et\u00a0al (2013) Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N\u00a0Engl J Med 369:438\u2013447","DOI":"10.1056\/NEJMoa1300439"},{"key":"3323_CR24","doi-asserted-by":"crossref","unstructured":"Naumann-Winter F, Greb A, Borchmann P et\u00a0al (2012) First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. Cochrane Database Syst Rev","DOI":"10.1002\/14651858.CD004626.pub3"},{"key":"3323_CR25","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","volume":"112","author":"Palumbo","year":"2008","unstructured":"Palumbo A, Bringhen S, Liberati AM et\u00a0al (2008) Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 112:3107\u20133114","journal-title":"Blood"},{"key":"3323_CR26","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2004-02-0408","volume":"104","author":"Palumbo","year":"2004","unstructured":"Palumbo A, Bringhen S, Petrucci MT et\u00a0al (2004) Intermediate-dose melphalan improves survival of myeloma patients aged\u00a050 to 70: results of a randomized controlled trial. Blood 104:3052\u20133057","journal-title":"Blood"},{"key":"3323_CR27","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/0277-5379(88)90160-5","volume":"24","author":"Peest","year":"1988","unstructured":"Peest D, Deicher H, Coldewey R et\u00a0al (1988) Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMP. Eur J Cancer Clin Oncol 24:1061\u20131067","journal-title":"Eur J Cancer Clin Oncol"},{"key":"3323_CR28","doi-asserted-by":"crossref","unstructured":"San Miguel JF, Schlag R, Khuageva NK et\u00a0al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N\u00a0Engl J Med 359:906\u2013917","DOI":"10.1056\/NEJMoa0801479"},{"key":"3323_CR29","doi-asserted-by":"crossref","unstructured":"Terpos E, Morgan G, Dimopoulos MA et\u00a0al (2013) International myeloma working group recommendations for the treatment of multiple myeloma related bone disease. J\u00a0Clin Oncol 31:2347\u20132357","DOI":"10.1200\/JCO.2012.47.7901"},{"key":"3323_CR30","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","volume":"113","author":"Weiss","year":"2009","unstructured":"Weiss BM, Abadie J, Verma P et\u00a0al (2009) A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113:5418\u20135422","journal-title":"Blood"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-013-3323-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-013-3323-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-013-3323-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T13:34:22Z","timestamp":1596807262000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-013-3323-7"}},"subtitle":["Was ist gesichert?"],"short-title":[],"issued":{"date-parts":[[2013,11,9]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["3323"],"URL":"https:\/\/doi.org\/10.1007\/s00108-013-3323-7","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,9]]}}}